PMID- 32103896
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20220413
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 14
DP  - 2020
TI  - Potential Use of Microbial Surfactant in Microemulsion Drug Delivery System: A 
      Systematic Review.
PG  - 541-550
LID - 10.2147/DDDT.S232325 [doi]
AB  - BACKGROUND: Microemulsions drug delivery systems (MDDS) have been known to 
      increase the bioavailability of hydrophobic drugs. The main challenge of the MDDS 
      is the development of an effective and safe system for drug carriage and 
      delivery. Biosurfactants are preferred surface-active molecules because of their 
      lower toxicity and safe characteristics when compared to synthetic surfactants. 
      Glycolipid and lipopeptide are the most common biosurfactants that were tested 
      for MDDS. The main goal of the present systematic review was to estimate the 
      available evidence on the role of biosurfactant in the development of MDDS. 
      SEARCH STRATEGY: Literature searches involved the main scientific databases and 
      were focused on the period from 2005 until 2017. The Search filter composed of 
      two items: "Biosurfactant" and/or "Microemulsion." INCLUSION CRITERIA: 
      Twenty-four studies evaluating the use of biosurfactant in MDDS were eligible for 
      inclusion. Among these 14 were related to the use of glycolipid biosurfactants in 
      the MDDS formulations, while four reported using lipopeptide biosurfactants and 
      six other related review articles. RESULTS: According to the output study 
      parameters, biosurfactants acted as active stabilizers, hydrophilic or 
      hydrophobic linkers and safety carriers in MDDS, and among them glycolipid 
      biosurfactants had the most application in MDDS formulations. CONCLUSION: 
      Synthetic surfactants could be replaced by biosurfactants as an effective 
      bio-source for MDDS due to their excellent self-assembling and emulsifying 
      activity properties.
CI  - (c) 2020 Ohadi et al.
FAU - Ohadi, Mandana
AU  - Ohadi M
AD  - Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University 
      of Medical Sciences, Kerman, Iran.
FAU - Shahravan, Arash
AU  - Shahravan A
AD  - Endodontology Research Center, Kerman University of Medical Sciences, Kerman, 
      Iran.
FAU - Dehghannoudeh, Negar
AU  - Dehghannoudeh N
AD  - Faculty of Arts and Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Eslaminejad, Touba
AU  - Eslaminejad T
AD  - Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University 
      of Medical Sciences, Kerman, Iran.
FAU - Banat, Ibrahim M
AU  - Banat IM
AUID- ORCID: 0000-0001-8964-2840
AD  - Faculty of Life & Health Sciences, University of Ulster, Coleraine BT52 1SA, N. 
      Ireland, UK.
FAU - Dehghannoudeh, Gholamreza
AU  - Dehghannoudeh G
AD  - Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University 
      of Medical Sciences, Kerman, Iran.
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical 
      Sciences, Kerman, Iran.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Systematic Review
DEP - 20200205
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Drug Carriers)
RN  - 0 (Emulsions)
RN  - 0 (Glycolipids)
RN  - 0 (Lipopeptides)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Surface-Active Agents)
SB  - IM
MH  - Drug Carriers/chemistry
MH  - *Drug Delivery Systems
MH  - Emulsions
MH  - Glycolipids/chemistry
MH  - Humans
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Lipopeptides/chemistry
MH  - Pharmaceutical Preparations/*administration & dosage/chemistry
MH  - Surface-Active Agents/*chemistry
PMC - PMC7008186
OTO - NOTNLM
OT  - biosurfactant
OT  - drug delivery systems
OT  - lipopeptide
OT  - microemulsion
OT  - systematic review glycolipid
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/02/28 06:00
MHDA- 2020/10/30 06:00
PMCR- 2020/02/05
CRDT- 2020/02/28 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2020/01/15 00:00 [accepted]
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
PHST- 2020/02/05 00:00 [pmc-release]
AID - 232325 [pii]
AID - 10.2147/DDDT.S232325 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2020 Feb 5;14:541-550. doi: 10.2147/DDDT.S232325. 
      eCollection 2020.